Erasca Inc ($ERAS) received 16 mentions over a 12-month period from November 2025 through July 2026, discussed by two distinct FinTwit voices. @jacobplieth contributed 9 mentions while @adamfeuerstein contributed 7 mentions, establishing biotech as the dominant voice category for this ticker. The stock first appeared in the archive on 2025-11-19 and continued to be discussed through mid-July 2026.

@adamfeuerstein's recent commentary focused on $ERAS data disclosures and capital raises, characterizing the company's approach to releasing information and questioning the efficacy and safety profile of its pipeline candidates. Discussion centered on competitive positioning in pancreatic cancer treatment and comparisons with other programs in the space, with @adamfeuerstein raising concerns about clinical validation and competitive advantages relative to other pipeline programs.